| 查看: 278 | 回复: 0 | |||
zlwcw木虫 (著名写手)
|
[交流]
【讨论】TERMINATION OF ACQUISITION AGREEMENT WITH WUXI PHARMATECH
|
|
CHARLES RIVER ANNOUNCES MUTUAL TERMINATION OF ACQUISITION AGREEMENT WITH WUXI PHARMATECH – Board of Directors Approves $500 Million Stock Repurchase Plan – – Special Stockholder Meeting Canceled – – Second-Quarter Earnings Release and Conference Call Rescheduled – WILMINGTON, MA, July 29, 2010 – Charles River Laboratories International, Inc. (NYSE: CRL), a leading global provider of research models and associated services and of preclinical drug development services, today announced that it has mutually agreed with WuXi PharmaTech (Cayman) Inc. (NYSE: WX) to terminate their previously announced acquisition agreement. The Company also announced that its Board of Directors has authorized a new $500 million stock repurchase program. The termination agreement provides for Charles River to pay WuXi a $30 million breakup fee for full satisfaction of the parties’ obligations under the acquisition agreement and includes mutual releases of any claims and liabilities arising out of or relating to the acquisition agreement. As a result of the termination of the acquisition agreement, the special meeting of Charles River stockholders to be held on August 5, 2010 has been canceled. James C. Foster, Chairman, President and Chief Executive Officer said, “We believed that this transaction, which would have created the premier early-stage contract research organization, would have resulted in long-term strategic benefits for our business and our shareholders. We also value our stockholders’ views and given their concerns about the proposed transaction, and our commitment not to proceed without their support, we have decided that terminating the transaction is the appropriate action to take. “Although we are disappointed in the outcome of the proposed transaction, our overall strategy remains unchanged. We intend to be the premier early-stage CRO and will continue to build our early development capabilities – specifically our discovery services – in order to support our clients’ efforts across a broader portion of the drug development pipeline. We will enhance our portfolio of essential products and services, deepen our scientific expertise and maintain our standards of exceptional client service, all of which distinguish Charles River as an industry leader and make us the strategic partner of choice in early-stage drug development.” “The Board’s action to authorize a new stock repurchase plan at this time reflects both its belief that our stock price is substantially undervalued and also its faith in Charles River’s future prospects. Repurchasing our stock is another means of enhancing earnings growth and improving stockholder value,” he concluded. Board Authorizes Stock Repurchase Plan Charles River’s Board of Directors has authorized the repurchase of up to $500 million of its common stock. The Company is currently exploring alternatives for timely execution. The stock purchases may be made from time to time through a variety of methods, including open market repurchases such as block trades, 10b5-1 plans or otherwise in compliance with Rule 10b-18 of the federal securities laws and/or privately negotiated transactions. Funds for the repurchases are expected to come from cash on hand, cash generated by operations, our existing credit facilities or other financing. Charles River has previously repurchased approximately 11 million shares under its prior $600 million stock repurchase authorization, and as of July 15, 2010, had approximately 66.3 million shares of common stock outstanding. That authorization, under which there was a remaining balance of approximately $145 million, has been canceled. Repurchases may be commenced or suspended at any time or from time to time without prior notice, depending on our view of market conditions and other factors. There are currently no specific plans for the shares that may be purchased under the program. |
回复此楼» 猜你喜欢
考研调剂：国家蛋白质科学中心（国家重点实验室）和安徽医科大学基础医学院联培
已经有4人回复
-
华南理工大学 基础医学学硕和临床医学学硕调剂
已经有11人回复
-
药物学论文润色/翻译怎么收费?
已经有171人回复
-
北京协和医学院杰青课题组招聘科研助理
已经有0人回复
-
北京协和医学院杰青课题组招聘科研助理
已经有0人回复
-
求助中国药典1995年版、二部
已经有0人回复
-
北京协和医学院杰青课题组招聘科研助理
已经有0人回复
-
使用MolAICal生成小分子CHARMM力场拓扑和参数文件
已经有0人回复
-
求助https://www.pnas.org/doi/10.1073/pnas.2535777123 全文
已经有0人回复
-
扩散模型生成分子目前痛点，改进方向有哪些，论文创新性卡住了现在
已经有0人回复
-
求解答药物生成模型痛点以及创新点，扩散模型创新
已经有0人回复
找到一些相关的精华帖子，希望有用哦~
Elements of information theory 2nd 信息论基础（第二版英文版）
已经有135人回复
- with the weight of adsorbate 如何理解（关于动态吸附）
已经有4人回复
- 求问 arabian journal of chemistry的英文缩写，感激不尽
已经有6人回复
- Journal of Micromechanics and Microengineering 投稿状态求助
已经有7人回复
- WuXi PharmaTech Acquires Abgent, a Leading Producer of Biological Research
已经有6人回复
- 强烈求助Error termination request processed by link 9999错误
已经有17人回复
- 【求助】Error termination request processed by link 9999是什么错误？程序在下面
已经有13人回复
- 【资源】Standard Handbook of Petroleum and Natural Gas Engin
已经有3人回复
点击这里搜索更多相关资源科研从小木虫开始，人人为我，我为人人
10